Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040-MedSci.cn

Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040

He, AR; Yau, T; Hsu, C; Kang, YK; Kim, TY; Santoro, A; Sangro, B; Melero, I; Kudo, M; Hou, MM; Matilla, A; Tovoli, F; Knox, JJ; El-Rayes, BF; Acosta-Rivera, M; Neely, J; Shen, Y; Tschaika, M; El-Khoueiry, AB

JOURNAL OF CLINICAL ONCOLOGY, 2020; 38 (4):

科室
- - 订阅+
  - 更多科室
工具
服务